- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07315282
Effekten av orale jernkosttilskudd på insulin- og glukosemetabolisme hos overvektige og overvektige kvinner
Effekten av orale jernpreparater på insulin- og glukosestoffskifte hos overvektige og overvektige kvinner
The study will be a randomized, double-blind, 17-day metabolic intervention trial including 14 days of high-dose or low-dose iron supplementation. A total of 70 overweight or obese (OW/OB) women will be enrolled. Participants will be individually randomized into either the high-iron or low-iron group.
Women in the low-iron group will receive 15 mg of iron as ferrous fumarate daily for 14 days, while women in the high-iron group will receive 195 mg of iron as ferrous sulfate daily for 14 days.
The study consists of three visits in total. On Day 0, a fasting blood sample will be collected and an OGTT will be performed, with additional blood samples collected at 1 hour and 2 hours post-OGTT. The OGTT will be repeated on Day 14, after 14 days of oral iron supplementation, and again on Day 17, four days after oral iron supplementation has been stopped
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Omar Obeid
- Telefonnummer: +961 1 350 000
- E-post: oo01@aub.edu.lb
Studiesteder
-
-
-
Beirut, Libanon
- Rekruttering
- American University of Beirut
-
Ta kontakt med:
- Omar Obeid, PhD
- Telefonnummer: +961 1 350 000
- E-post: oo01@aub.edu.lb
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- BMI ≥ 27.5 kg/m2
- serum ferritin <30 μg/L
- hemoglobin ≥ 11 g/dl
- fasting blood glucose < 5.6 mmol/L
Exclusion Criteria:
- intravenous or high dose oral iron in the preceding 2 months
- medical disorders are known to affect iron absorption or metabolism, or T2DM
- cigarette smoking
- recent blood transfusion or major blood loss
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: high-dose iron supplementation
195 mg iron as ferrous sulfate daily for 14 days |
3 x 65 mg iron as ferrous sulfate |
|
Aktiv komparator: low-dose iron supplementation
15 mg iron as ferrous fumarate daily for 14 days |
3 x 5 mg iron as ferrous sulfate |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood glucose increase during OGTT Day 0
Tidsramme: Day 0
|
Blood glucose increase during OGTT before the intake of oral iron for 14 days |
Day 0
|
|
Blood glucose increase during OGTT Day 14
Tidsramme: Day 14
|
Blood glucose increase during OGTT after the intake of oral iron for 14 days |
Day 14
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Insulin increase during OGTT Day 0
Tidsramme: Day 0
|
Insulin increase during OGTT before the intake of oral iron for 14 days |
Day 0
|
|
Insulin increase during OGTT Day 14
Tidsramme: Day 14
|
Insulin increase during OGTT after the intake of oral iron for 14 days |
Day 14
|
|
Serum Hepcidin Day 0
Tidsramme: Day 0
|
Serum Hepcidin measured before the intake of oral iron |
Day 0
|
|
Serum Hepcidin D14
Tidsramme: Day 14
|
Serum Hepcidin measured after the intake of oral iron |
Day 14
|
|
Serum Ferritin Day 0
Tidsramme: Day 0
|
Serum Ferritin measured before the intake of oral iron |
Day 0
|
|
Serum Ferritin Day 14
Tidsramme: Day 14
|
Serum Ferritin measured after the intake of oral iron |
Day 14
|
|
Soluble Transferrin Receptor (sTfR) Day 0
Tidsramme: Day 0
|
sTfR measured before the intake of oral iron |
Day 0
|
|
Soluble Transferrin Receptor (sTfR) Day 14
Tidsramme: Day 14
|
sTfR measured after the intake of oral iron |
Day 14
|
|
Hemoglobin Day 0
Tidsramme: Day 0
|
Hemoglobin measured before the intake of oral iron |
Day 0
|
|
Hemoglobin Day 14
Tidsramme: Day 14
|
Hemoglobin measured after the intake of oral iron |
Day 14
|
|
C-reactive protein (CRP) Day 0
Tidsramme: Day 0
|
CRP measured before the intake of oral iron |
Day 0
|
|
C-reactive protein (CRP) Day 14
Tidsramme: Day 14
|
CRP measured after the intake of oral iron |
Day 14
|
|
Alpha-1-acid glycoprotein (AGP) Day 0
Tidsramme: Day 0
|
AGP measured before the intake of oral iron |
Day 0
|
|
Alpha-1-acid glycoprotein (AGP) Day 14
Tidsramme: Day 14
|
AGP measured after the intake of oral iron |
Day 14
|
|
Serum Iron Day 0
Tidsramme: Day 0
|
Serum Iron measured before the intake of oral iron |
Day 0
|
|
Serum Iron Day 14
Tidsramme: Day 14
|
Serum Iron measured after the intake of oral iron |
Day 14
|
|
Total Iron Binding Capacity (TIBC) Day 0
Tidsramme: Day 0
|
TIBC measured before the intake of oral iron |
Day 0
|
|
Total Iron Binding Capacity (TIBC) Day 14
Tidsramme: Day 14
|
TIBC measured after the intake of oral iron |
Day 14
|
|
Transferrin Saturation (TSAT) Day 0
Tidsramme: Day 0
|
TSAT measured before the intake of oral iron |
Day 0
|
|
Transferrin Saturation (TSAT) Day 14
Tidsramme: Day 14
|
TSAT measured after the intake of oral iron |
Day 14
|
|
Transferrin Saturation (TSAT) Day 17
Tidsramme: Day 17
|
TSAT measured at endpoint |
Day 17
|
|
Total Iron Binding Capacity (TIBC) Day 17
Tidsramme: Day 17
|
TIBC measured at endpoint |
Day 17
|
|
Serum Iron Day 17
Tidsramme: Day 17
|
Serum Iron measured at endpoint |
Day 17
|
|
Serum Hepcidin Day 17
Tidsramme: Day 17
|
Serum Hepcidin measured at endpoint |
Day 17
|
|
Insulin increase during OGTT Day 17
Tidsramme: Day 17
|
Insulin increase during OGTT at Endpoint |
Day 17
|
|
Blood glucose increase during OGTT Day 17
Tidsramme: Day 17
|
Blood glucose increase during OGTT at Endpoint |
Day 17
|
|
Fasting blood glucose Day 0
Tidsramme: Day 0
|
Fasting blood glucose before iron intake |
Day 0
|
|
Fasting blood glucose Day 14
Tidsramme: Day 14
|
Fasting blood glucose after iron intake |
Day 14
|
|
Fasting blood glucose Day 17
Tidsramme: Day 17
|
Fasting blood glucose at Endpoint |
Day 17
|
|
Fasting insulin Day 0
Tidsramme: Day 0
|
Fasting insulin before iron intake |
Day 0
|
|
Fasting insulin Day 14
Tidsramme: Day 14
|
Fasting insulin after iron intake |
Day 14
|
|
Fasting insulin Day 17
Tidsramme: Day 17
|
Fasting insulin at Endpoint |
Day 17
|
|
Blood glucose profile measured over the 14 days
Tidsramme: Day 0 - Day 14
|
blood glucose profile measured by wearable FreeStyle Libre Sensor |
Day 0 - Day 14
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FIND
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .